Episode 169 - January 16, 2026

The biotech panel analyzes the sentiment and key takeaways from the recent JPMorgan conference, focusing on market dynamics and investment strategies for 2026. Discussions revolve around the surprising lack of M&A activity, which some view as a positive sign of companies being financially strong and choosing to remain independent. Investor sentiment is gauged at a "7 out of 10," indicating healthy optimism without overheating. The panel also explores Moderna's updated guidance and potential patent litigation, AbbVie's China deal, and AI's growing role in pharma, including a collaboration between NVIDIA and Lilly. Additionally, regulatory updates from the FDA are examined, along with the continued focus on obesity drugs and recent data readouts in areas like DMD and cystic fibrosis.